Inhibition of 3-mercaptopyruvate sulfurtransferase enhances CD8⁺ T-cell antitumor immunity

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Hydrogen sulfide (H₂S) is a redox-active gasotransmitter implicated in tumor progression and immune regulation. The enzyme 3-mercaptopyruvate sulfurtransferase (3-MST) is a key contributor to endogenous H₂S and polysulfide production, but its role in tumor–immune interactions remains poorly defined. Here, we show that 3-MST is the most abundantly expressed H₂S-synthesizing enzyme in human renal cell carcinoma cells (RCC) and that high 3-MST expression correlates with reduced patient survival. Pharmacological inhibition of 3-MST lowered intracellular H₂S levels in Renca renal carcinoma cells, suppressed proliferation, induced apoptosis, and increased surface expression of the immunogenic markers CD70, CD86, and PD-L1. In immune cells, partial inhibition of 3-MST promoted T cell activation, as evidenced by increased CD69 expression on both CD4⁺ helper and CD8⁺ cytotoxic T cells. In contrast, complete inhibition of 3-MST, achieved by high concentrations of the inhibitor, modestly reduced CD8⁺ T cell proliferation. Functionally, 3-MST inhibition potentiated antigen-specific CD8⁺ T cell-mediated killing of tumor cells, an effect further amplified by PD-L1 blockade. These results establish 3-MST as a redox-sensitive metabolic driver of tumor growth and immune evasion in RCC and demonstrate that its inhibition can boost antitumor immune responses, offering a potential avenue for combination immunotherapy.

Article activity feed